• What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, et al., IJMS. 24 mai 2019;20(10):2564.

  • Preliminary results of a 68 Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making, Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, et al. , Prostate. 17 août 2019;pros.23869

  • Potential for Nuclear Medicine Therapy for Glioblastoma Treatment, Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, et al., Front Pharmacol. 10 juill 2019;10:772.

  • Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches, Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, et al., Front Med. 4 juin 2019;6:124.

  • Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al., Cancers. 31 août 2019;11(9):1282.

  • Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT, Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bodet-Milin C, Bailly C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Oncotarget 2018, 9:27502-27513

  • Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging, Le Bihan T, Navarro AS, Le Bris N, Le Saëc P, Gouard S, Haddad F, Gestin JF, Chérel M, Faivre-Chauvet A, Tripier R, Org Biomol Chem. 2018, 16:4261-4271

  • Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C, Oncotarget 2018, 9:9061-9072

  • Pretargeting in the context of theranostics and companion diagnostics in nuclear oncology. Barbet J. Clin Transl Imaging. (2018) 1-9.

    Translational molecular imaging in exocrine pancreatic cancer. Cornelissen B, Knight JC, Mukherjee S, Evangelista L, Xavier C, Caobelli F, Del Vecchio S, Rbah-Vidal L, Barbet J, de Jong M, van Leeuwen FWB. Eur J Nucl Med Mol Imaging. (2018)45, 2442-2455.

    Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study, Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C , Clin Cancer Res. 2018, 24:5219-5224 IF 10.199 JIF 94.820

  • Theranostic radioimmunotherapy (RIT) combined with immunotherapy : The best way to go ? Jean-François Chatal*, Med Res Innov, 2017 doi : 10.15761/MRI.1000119

    Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial : Innovative Radiopharmaceuticals in Oncology and Neurology. Front Med (Lausanne). 2017 Jan 11 ;3:74. doi : 10.3389/fmed.2016.00074. eCollection 2016.

    Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. C. Bailly et al. (accpeté pour publication dans Oncotarget)

    “Immuno-PET for Clinical Theranostic Approaches« . Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickaël Bourgeois, François Guérard, Ferid Haddad, Jacques Barbet, Michel Chérel, Françoise Kraeber-Bodéré, Thomas Carlier and Caroline Bodet-Milin. International Journal of Molecular Sciences 2017, 18 (1), 57 2017

    Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J. EJNMMI radiopharm. chem. (2017) 2 : 6. https://doi.org/10.1186/s41181-017-0026-8

    van Leeuwen FWB, Cornelissen B, Caobelli F, Evangelista L, Rbah-Vidal L, Del Vecchio S, Xavier C, Barbet J, de Jong M. EJNMMI radiopharm. chem. (2017) 2 : 15. https://doi.org/10.1186/s41181-017-0034-8

    Bourgeois M, Bailly C, Guerard F, Cherel M, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C. Radioimmunoconjugates for treating cancer : recent advances and current opportunities. Expert Opin Biol Ther 2017, 4 : 1-7 IF 3.684

    Frindel M, Le Saëc P, Beyler M, Navarro AS, Saï-Maurel C, Alliot C, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer. RSC Adv. 2017, 7 : 9272 IF 3.108

    Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C. Initial FDG-PET/CT predicts survival in adults ewing sarcoma family of tumors Oncotarget 2017, 8:77050-77060 IF 5.168